(QGEN) Qiagen N.V. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(QGEN) Qiagen N.V. Complete Analysis Pack
Download Your Competitive Advantage
This Qiagen N.V. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The page already shows a real preview of the actual report content, so you can review what you’ll get before buying. Purchase the full version to access the complete ready-to-use analysis.
Stars
QIAstat-Dx syndromic PCR panels
QIAstat-Dx syndromic PCR panels are QIAGEN’s clearest growth engine in clinical testing. The menu covers respiratory, gastrointestinal, and other multiplex panels, so each new system can drive recurring reagent sales. With an expanding installed base and broader assay use, it looks like a strong Star candidate by end-2025.
QIAcuity digital PCR systems
In 2025, QIAcuity stayed QIAGEN’s key dPCR growth engine, with adoption widening in research, translational, and clinical workflows. That fits a Star: fast market growth and rising penetration, not a mature cash cow. QIAGEN kept expanding the QIAcuity menu and placements through 2025, supporting share gains.
NGS library prep and gene panels
QIAGEN's NGS stack spans library prep kits, whole genome amplification, and predefined and custom panels. NGS keeps growing fast in oncology, hereditary testing, and applied genomics, so this unit fits a Stars slot in the BCG Matrix. QIAGEN has a real base here, but it still needs heavy R&D and commercial spend to defend share and widen its panel menu.
Companion diagnostics partnerships
QIAGEN's companion diagnostics ties with Sysmex, OncXerna Therapeutics, and Mirati keep its precision-oncology pipeline active, and this fits a Stars profile: high growth with rising share. These assays help match patients to biomarker-driven therapies, which is where oncology testing demand is growing fastest. QIAGEN reported $2.0 billion in 2024 revenue, giving it scale to push more co-developed tests.
Partners: Sysmex, OncXerna, Mirati.
Focus: biomarker-based treatment selection.
Edge: collaborations expand assay share.
Bioinformatics software and digital insight tools
QIAGEN’s software layer is a Star-like asset because it sits on top of growing molecular diagnostics and genomics workflows, where every extra sequencing or PCR run raises the need for interpretation. It also scales well: software adds recurring value without the same lab capex as instruments. QIAGEN’s latest filing showed about $2.0bn in annual sales, with software helping lift mix and stickiness.
- High-growth workflow layer
- Recurring, scalable economics
- Supports cross-sell and retention
QIAGEN’s Growth Engines: QIAstat-Dx and QIAcuity Lead
QIAGEN’s Stars are QIAstat-Dx and QIAcuity, with NGS and companion diagnostics also scaling in fast-growing markets. QIAstat-Dx and QIAcuity had the clearest 2025 growth profile, while QIAGEN’s 2024 revenue was about $2.0bn, giving it room to fund share gains.
| Star asset | Why it fits | 2025 signal |
|---|---|---|
| QIAstat-Dx | Multiplex PCR growth | Installed-base expansion |
| QIAcuity | dPCR adoption rising | Menu and placement growth |
What is included in the product
Detailed Word Document
Qiagen's BCG Matrix maps its diagnostics portfolio to spot stars, cash cows, question marks, and dogs for smart capital allocation.
Editable Excel File
One-page BCG Matrix for Qiagen N.V. that quickly spots growth and drag areas.
Reference Sources
Provides a credible source trail for Qiagen N.V. that speeds due diligence and strengthens confidence in key assumptions.
Cash Cows
Sample prep kits for nucleic acid purification
Sample prep kits for nucleic acid purification remain one of QIAGEN’s largest, most mature cash cows, with demand spread across research, diagnostics, and applied testing. The franchise benefits from recurring consumable sales from both manual and automated workflows, which supports steady cash generation even when unit growth slows. In QIAGEN’s latest reported results, this kind of recurring revenue base helped keep margins resilient and cash flow durable.
QuantiFERON-TB Gold Plus
QuantiFERON-TB Gold Plus is Qiagen’s leading interferon-gamma release assay for latent TB, and it sits in a mature testing market with durable, repeat demand from labs and clinics. Its large installed base and global use support steady cash flow, while the category’s scale matters given WHO still estimates about 1.25 million TB deaths in 2023. That is classic Cash Cow territory.
qPCR and RT-PCR consumables
QIAGEN's qPCR and RT-PCR consumables are a classic cash cow: labs use these reagents in gene expression, genotyping, and regulation studies every run, so demand is sticky and repeat-heavy. In FY2025, QIAGEN generated about $2.0 billion in net sales, and this consumables base helps support that steady cash flow with low reinvestment needs. Growth is modest, but the installed customer base keeps volumes recurring and margins resilient.
Human ID and forensic STR assays
QIAGEN’s Human ID and forensic STR assays are a classic cash cow: mature, niche workflows with repeat kit demand from forensic labs. This supports sticky sales and margin discipline more than fast growth. In 2024, QIAGEN reported net sales of about $2.1 billion and adjusted diluted EPS of $2.20.
- Repeat consumables drive revenue.
- Specialized lab workflows cut churn.
- Focus is retention, not expansion.
- Stable cash flow supports margins.
OEM consumables and repeat-use lab materials
QIAGEN's OEM consumables and repeat-use lab materials are classic cash cows: they are built into partner workflows, so demand is sticky and repeat orders keep coming. In 2024, QIAGEN generated about $1.97 billion in net sales, and this mature, installed-base business helps fund growth bets with steady cash flow.
- Recurring demand from embedded workflows
- Low churn versus one-off instrument sales
- Stable cash, not high-growth upside
QIAGEN’s Recurring Revenue Engine Runs on Mature Consumables
QIAGEN’s cash cows are mature consumables with repeat demand, led by sample prep kits, qPCR and RT-PCR reagents, QuantiFERON-TB Gold Plus, and Human ID assays. These lines sell into installed lab workflows, so churn is low and cash flow is steady. In FY2025, QIAGEN reported about $2.0 billion in net sales, showing the scale of this recurring base.
| Cash Cow | Why it matters | FY2025 data |
|---|---|---|
| Sample prep kits | Repeat consumables | Steady sales base |
| QuantiFERON-TB Gold Plus | Mature TB testing | WHO: 1.25M TB deaths in 2023 |
Get Your Copy
Qiagen N.V. Reference Sources
The Qiagen N.V. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content or hidden sections—just the full, professionally formatted report. Once purchased, it’s ready to download, use, and share right away.
Dogs
Legacy standalone PCR instrument lines
Legacy standalone PCR instrument lines sit in a crowded market, where larger platform vendors push higher-throughput systems and bundled consumables. Compared with newer digital and multiplex PCR tools, growth is modest and the installed base is mainly a harvest pool, not an expansion engine. QIAGEN’s newer QIAcuity and syndromic testing lines are the growth focus, while these older instruments keep cash but face slower demand.
Older manual purification accessories
Older manual purification accessories sit in the Dogs quadrant because they support legacy prep workflows that are being displaced by automation. These add-ons are usually commoditized, low-margin, and tied to shrinking installed bases, so their strategic share and growth stay weak versus Qiagen N.V.'s higher-value sample technologies.
Food contamination testing assays
Food contamination testing assays sit in a fragmented, price-sensitive applied market, so they fit as a Dog in Qiagen N.V.'s BCG Matrix. QIAGEN does participate, but this niche is not a core growth engine; in FY2025, the company’s focus stayed on diagnostics and genomics, where scale and margins are stronger. That makes food testing a low-priority use of capital versus higher-return areas.
Small prenatal and STD niche menus
QIAGEN N.V.'s small prenatal and STD niche menus look like Dogs by end-2025: they sit in crowded assay markets, face uneven reimbursement, and do not have the scale or brand pull of QuantiFERON. In QIAGEN's 2025 mix, these lines are likely low-growth, low-share pockets rather than core value drivers. Their role is more defensive than expansionary.
- Low share, weak growth.
- Heavy pricing pressure.
- Reimbursement stays uneven.
- Not QuantiFERON-scale assets.
That makes them better candidates for harvest, tight cost control, or selective pruning than for major reinvestment.
Low-volume custom lab service work
QIAGEN N.V.’s low-volume custom lab service work fits Dogs: it is bespoke, hard to scale, and usually brings limited repeat demand. Compared with consumables and platform sales, it has weaker margin leverage and less strategic pull, so it is a poor target for major capital spend.
- Low scale, low repeat demand
- Weak margin leverage
- Capital-light only
- Best kept niche or trimmed
QIAGEN’s Dog Products: Legacy, Pressured, and Deprioritized
Dogs in QIAGEN N.V.'s BCG mix are legacy PCR tools, manual prep add-ons, food testing assays, and small niche menus: low share, weak growth, and heavy price pressure. In FY2025, QIAGEN kept capital on QuantiFERON, QIAcuity, and syndromic testing, so these lines are harvest or prune candidates.
| Dog set | FY2025 read |
|---|---|
| Legacy PCR | Low growth |
| Manual prep | Commoditized |
| Food testing | Price pressured |
Question Marks
Liquid biopsy and cfDNA oncology
Liquid biopsy and cfDNA oncology is a Question Mark: the market is still growing at roughly 15%-20% a year, but Qiagen N.V. is not the share leader. With about €2.0 billion revenue in 2024, Qiagen has tools and partnerships, yet it still needs investment to turn promise into durable scale.
Custom NGS panels
Custom NGS panels fit a Question Mark for Qiagen N.V. because precision-medicine and translational-research demand is rising, but the field is crowded and Qiagen is still building share. Qiagen reported 2024 net sales of US$1.98 billion, yet custom panels need more scale to win against bigger NGS rivals. Growth is real, but so is the fight.
Broader oncology mutation, insertion, deletion, and fusion assays
Broader oncology mutation, insertion, deletion, and fusion assays sit in a fast-growing market: IARC counted 20 million new cancer cases in 2022, and cases may reach 35 million by 2050. QIAGEN has strong products, but share is not dominant across all targets, so this is still a Question Mark in BCG terms. It needs steady sales, menu expansion, and partner wins to avoid slipping toward Dogs.
Next-gen decentralized testing expansion
QIAGEN is pushing sample-to-insight automation into more clinical settings, but adoption outside its core accounts is still uneven, so this fits Question Mark territory. In 2024, QIAGEN reported net sales of about $1.97 billion, while its broader automation base is still building beyond established lab customers.
- Large clinical upside
- Uneven uptake outside core
- Needs more evidence
- High growth, uncertain share
The big issue is conversion speed, not demand size: if QIAGEN expands clinical pull-through, this can move toward a Star, but weak non-core penetration keeps it a bet, not a winner yet.
Emerging AI-enabled genomics workflows
AI-assisted genomics is still a developing field, but adoption is rising as labs use software to cut manual review time and raise call accuracy. QIAGEN already has workflow software and sample-to-insight tools, so this could scale into a Star if it wins more users and deepens differentiation. Right now, it fits a Question Mark because growth is real, but share and proof are still building.
- Growing demand for AI interpretation
- QIAGEN has relevant workflow tools
- Market position is still unproven
- Can become a Star with wider adoption
QIAGEN’s Growth Bets: Big Demand, Still Room to Win
QIAGEN’s Question Marks are growth markets where demand is rising, but share is still not dominant. Liquid biopsy, custom NGS panels, broad oncology assays, automation, and AI genomics all need more scale and proof, even as QIAGEN reported 2024 net sales of US$1.98 billion.
| Area | Signal |
|---|---|
| Liquid biopsy | 15%-20% growth |
| Oncology | 20M cases in 2022 |
| QIAGEN sales | US$1.98B in 2024 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.